Sign in →

Test Code C12 JAK2 V617F Mutation (Karyotyping) (NeoGenomics)

Important Note

It is now becoming evident that more than 90% of patients with conventionally-defined polycythemina vera (pv) carry the somatic JAK2 V617F mutation. However, the specific mutation is also found in other classical and atypical myeloproliferative neoplasms (MPN), albeit to a lesser extent. In contrast, JAK2 V617F has not been reported in patients with either reactive myeloproliferation or lymphoid disorders. Therefore, mutation screening for JAK2 V617F can be considered as a myeloid-specific clonality assay and it is diagnostically most useful in the evaluation of polycythemia.


Additional Codes


PowerChart: Not Available

MA Cerner: JAK2 V617F Mutation Detection

Specimen Requirement

Peripheral Blood: Purple-Top Tube 5-10 mL

Bone Marrow Aspirate: Purple-Top Tube 1-2 mL

Useful For

Aiding in the distinction between a reactive cytosis and a chronic myeloproliferative disorder


7 days after the specimen arrives at the NeoGenomics testing site.

CPT Code Information

81270 Gene Analysis: Tier 1 Procedure; JAK2 (Janus Kinase 2) gene analysis, p. Val617Phe (V617F) variant 
(Typically billing is processed by NeoGenomics

LOINC Code Information

43399-5 Blood or Bone Marrow

Test Method

Molecular Polymerase Chain Reaction

Reference Values

Not applicable